IKS Health shares surged nearly 10% to an intraday high of ₹1,573.80 on Friday, April 24, before paring gains to trade at ₹1,460.10 by 12:26 pm, representing a 1.73% gain from Thursday's close of ₹1,435.30. According to The Hindu BusinessLine, the stock opened at ₹1,476.90 with unusually heavy trading volumes of 33.35 lakh shares worth ₹503.84 crore, indicating significant investor interest. The heavy trading activity is notable given the stock's free-float market cap of ₹7,192 crore, suggesting unusual market participation.
The company announced a definitive agreement after market hours on Thursday, April 23, under which IKS Health's US subsidiary will acquire TruBridge, Inc. (NASDAQ: TBRG) at $26.25 per share in cash. As reported by The Hindu BusinessLine, the transaction values TruBridge at an enterprise value of approximately $557 million. The acquisition will be funded primarily through roughly $600 million in new debt underwritten by Citibank, JPMorgan Chase, and Deutsche Bank, placing post-closing leverage at approximately three times the combined entity's EBITDA. The deal requires shareholder approvals from both companies and US antitrust clearance, with closure expected in the second quarter of fiscal year 2027.
According to investor documents filed with BSE and NSE, the acquisition combines TruBridge's EHR platform serving over 700 rural hospital clients with IKS Health's AI-driven care enablement platform. As reported by The Hindu BusinessLine, management is targeting combined EBITDA of approximately ₹3,000 crore by FY2030, against a current consolidated figure of around ₹1,000 crore. The deal is projected to be earnings-per-share accretive from the first full year post-closing, with IKS Health also identifying a cross-sell opportunity of over $575 million within TruBridge's existing client base.
Despite the acquisition announcement, IKS Health shares remain well below their 52-week high of ₹1,876 hit in June 2025 and are down 13.21% year-to-date, underperforming the Nifty 500's 5.62% decline over the same period. According to The Hindu BusinessLine, sell orders currently dominate at 65% of the order book versus 35% on the buy side, suggesting initial enthusiasm is meeting resistance at higher levels. The stock's current trading level reflects the market's assessment of the acquisition's strategic value and execution risks.
